Atherosclerotic Cardiovascular Disease

This listicle highlights 5 major approvals and 5 trial updates in cardiovascular care from 2024.

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with diabetes in the BPROAD trial.

A 6-year longitudinal study, involving more than 200,000 adults, reported a notable rise in dyslipidemia incidence during the COVID-19 pandemic.

A new AHA statement highlights the benefits of lipoprotein apheresis for familial hypercholesterolemia and urges broader access to the underutilized therapy.

Elucid has received 510(k) clearance for its PlaqueIQ™ imaging analysis software to help physicians diagnose cardiovascular disease.

Subclinical atherosclerosis burden and its progression are independently linked to the risk of death from any cause in asymptomatic individuals.

Expert clinical consensus from the National Lipid Association finds ApoB testing is useful to stratify ASCVD risk more accurately than LDL-C.

The approval to GE Healthcare's cyclotron-produced radioactive diagnostic drug provides another option to adequately identify significant coronary artery disease.

A Q&A with Nihar Desai, MD, on the PROMPT-Lipid trial and the potential of advancing technology for improving patient care in pragmatic ways.

At the Family Heart Summit, Nihar Desai, MD, discussed using EMR alerts to improve lipid therapy for high-risk ASCVD, as shown in the PROMPT-Lipid trial.

The analysis of LDL-C Management Trends observed disparities in LDL-C goal attainment by race, gender, and age.

A new study revealed those who consume a moderate amount of coffee or caffeine had a 48.1% and 40.7% reduced risk for developing cardiometabolic multimorbidity.

Lifetime statin treatment increased quality-of-life-adjusted survival in men and women aged ≥70 years with and without previous CVD in the United Kingdom.

New study finds ASCVD risk score often misses at-risk patients for first acute coronary syndrome, highlighting need for better prediction methods.

The August 2024 cardiology month in review highlights critical data from the European Society of Cardiology Congress 24 and the latest updates on finerenone.

A single blood test using hsCRP, LDL-C, and Lp(a) levels can predict cardiovascular risk for women up to 30 years, emphasizing personalized care.

Sara Diaz Saravia, MD, discusses a study from ESC Congress 2024 examining the utility of cancer history in women as a predictor of subclinical atherosclerosis.

Women with endometriosis experienced a 20% greater risk of cardiac outcomes compared with women without endometriosis.

Intensive lipid-lowering treatment regimens were linked to a notable reduction in three-point MACE risk and ACS recurrence versus background statin therapy.

Combination therapy with ezetimibe led to a greater reduction in LDL-C levels than statin monotherapy, but no significant effect on MACE outcomes.

A systematic review identified a notable link between the first year of statin discontinuation and the risk of adverse cardiovascular outcomes.

Higher olpasiran doses sustained a ~50% placebo-adjusted mean reduction in Lp(a) levels nearly 1 year after the final dose.

The July 2024 cardiology month in review spotlights new data from obicetrapib, a deep dive into risk stratification algorithms, and studies on the need for optimal care.

A study cautions the AHA's new PREVENT equations may underprescribe statins and antihypertensives, potentially causing 107,000 more ASCVD events in 10 years.

Despite recommendations, an analysis of more than 3.2 million youths suggests fewer than 15% of children/adolescents receive lipid screening.